3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
274
Magnetic Resonance Spectroscopy
226
pembrolizumab
225
Carboplatin
178
Biopsy
165
Cisplatin
162
Nivolumab
157
Cyclophosphamide
146
Paclitaxel
124
Radiotherapy
123
Gemcitabine
114
Bevacizumab
92
durvalumab
91
Dexamethasone
87
Rituximab
80
Oxaliplatin
80
venetoclax
73
atezolizumab
70
Doxorubicin
70
Fluorouracil
69
Docetaxel
69
Capecitabine
68
Etoposide
66
Radiosurgery
65
Ipilimumab
63
Radiation
60
Prednisone
60
Cytarabine
60
Lenalidomide
59
fludarabine
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
trebananib
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled